skip to main content
UK Health Security Agency

KARPAS-1106P

KARPAS-1106P

Catalogue No.

06072607

Cell Line Name

KARPAS-1106P

Cell Line Description

A human B cell lymphoma established from a pleural effusion of a 23-year-old woman with mediastinal lymphoblastic B-cell non-Hodgkin's lymphoma. This cell line does not express BCL2.

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Tissue of Origin

Blood (peripheral)

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10,12
D5S818: 8,14
D7S820: 9,13
D13S317: 9,11
D16S539: 9
TH01: 6
TPOX: 9,11
vWA: 18,20

Karyotype

Refer to Nacheva et al., 1994

Disease

Lymphoma

Culture Conditions

Cell Type

Lymphoblastoid

Subculture Routine

If starting from a frozen ampoule the cryoprotectant should be removed. Add thawed cells to a conical based centrifuge tube e.g. 15ml tube, slowly add 4 ml of culture medium to the tube. Take a sample of the cell suspension, e.g. 100µl, to count cells. Centrifuge the cell suspension at low speed i.e. 100 - 150 x g for a maximum of 5 minutes. Remove medium and resuspend the cell pellet at a density of 3 - 5 x 100,000 cells/ml in fresh medium containing 20% serum. Incubate flask at 37°C; 5 - 7% CO₂. Check daily. Keep flask in a vertical position until the cells reach the exponential phase of growth. This can take up to 7 days. Once the culture is established the serum concentration can be reduced to 10%.Maintain cultures between 3 - 9 x100,000 cells/ml; 5% CO₂; 37°C. Doubling time approximately 60-100 hours. Spherical cells growing in clusters in suspension.

Culture Medium

RPMI 1640 + 2mM Glutamine + 10 - 20% Foetal Bovine Serum (FBS)

Growth Mode

Aggregates in suspension

Additional Info

Depositor

Dr Abraham Karpas, Department of Haematology, University of Cambridge, MRC Centre, Hills Road, Cambridge, UK

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Nacheva et al., (1994) B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood 84, 3422-8.

Bibliography

Tamura et al. (1998). Delineation of the breakpoint at 18q21.1 in a cell line (Karpas1106) derived from mediastinal B-cell lymphoma by fluorescence in situ hybridization with multiple YAC clones. Int J Cancer 78(1): 100-5.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: KARPAS-1106P (ECACC 06072607).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.